Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 18/20 | 0.42 |
| ▸ | CHKB | Q9Y259 | 7/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176132 | 1.00 | CHKA (0.42) | CHKACHKBTMIGD3HTR2CHTR2B | |
| SCHEMBL21176120 | 0.90 | CHKA (0.45) | CHKACHKB | |
| SCHEMBL19820509 | 0.90 | CHKA (0.45) | CHKACHKB | |
| SCHEMBL29353035 | 0.88 | CDK1 (0.36) | CHKACHKBADORA3 | |
| SCHEMBL29354360 | 0.87 | CHKA (0.36) | CHKACHKB | |
| SCHEMBL29350248 | 0.79 | CHKA (0.36) | CHKACHKBADORA3 | |
| SCHEMBL29354564 | 0.79 | CHKA (0.38) | CHKACHKB | |
| SCHEMBL21594947 | 0.76 | ADORA3 (0.35) | TMIGD3HTR2CHTR2BADORA3 | |
| SCHEMBL19820532 | 0.75 | CHKA (0.66) | CHKACHKB | |
| SCHEMBL19820535 | 0.75 | CHKA (0.66) | CHKACHKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-06-16 | — | — | US | disclosed |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | DCK, CHKA, ADK | CHKA 2/4885CHKB 6/4885TMIGD3 3258/4885 |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | DCK, CHKA, ADK | CHKA 2/4885CHKB 6/4885TMIGD3 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.